Abha Kundi’s Insights

40 total results. Page 1 of 4.

Alerts
Customs Cleared, Charges Pending: Counterfeit Ozempic Indictment Makes the Drug Supply Chain Security Act (DSCSA) an Import Compliance Issue
Alerts
No Immunity: Why Wellness and Longevity Brands Can Get Sued Before the FDA Ever Calls
Alerts
Tele-Vision: How Recent FDA and SEC Actions Forecast a Sharper Focus on Telehealth Prescribing Models
Alerts
How a Warning Letter Became a Wellness Playbook
Alerts
RUO-ined: Five Peptide Vendors Learn That ‘Research Use Only’ Is Not a Legal Strategy
Press Release
AFS Welcomes 2026 Fellows Class, Building on a Decade of Leadership Development
Alerts
A Refill on Relief: FDA Extends DSCSA Exemption for Small Dispensers as Assessment Begins
News
Kundi Featured on FDA Committee Peptide Vote
News
Kundi Quoted on FDA Committee Approval of Peptide Compounds
Alerts
The (Pep)Tides Turn: FDA Panel Recommends Six of Seven for Compounding
Alerts
Reinventing the Wheel: FDA’s Hub-and-Spoke Fix for Drug Manufacturing Registration
Alerts
50 Shades of Legally Gray: FDA’s Juicy Peptide Cliffhanger